Weiru Chi
YOU?
Author Swipe
View article: XBP1s Mediates Cross‐resistance to Combination Treatment of CDK4/6 Inhibitors plus Endocrine Therapy in Breast Cancer
XBP1s Mediates Cross‐resistance to Combination Treatment of CDK4/6 Inhibitors plus Endocrine Therapy in Breast Cancer Open
CDK4/6 inhibitors combined with endocrine therapy is the standard treatment for patients with hormone receptor‐positive (HR+)/human epidermal growth factor receptor 2‐negative (HER2−) metastatic breast cancer (MBC). However, the inevitable…
View article: JCAD-Derived from Plasma Exosomes: Promoting Tumor Cell Progression and Predicting Poor Outcomes in Breast Cancer
JCAD-Derived from Plasma Exosomes: Promoting Tumor Cell Progression and Predicting Poor Outcomes in Breast Cancer Open
Background: Breast cancer has the highest incidence among all cancers in women, and the prognosis of breast cancer is strongly linked to the stage of the disease. As one of the components found in liquid biopsy samples, exosomes are membra…
View article: PPARG Activation of Fatty Acid Metabolism Drives Resistance to Anti-HER2 Therapies in HER2-Positive Breast Cancer
PPARG Activation of Fatty Acid Metabolism Drives Resistance to Anti-HER2 Therapies in HER2-Positive Breast Cancer Open
HER2-positive breast cancer, which accounts for approximately 15-20% of all breast cancers, is characterized by its aggressive recurrence, metastasis and reduced survival. Despite advances in anti-HER2 therapies, many patients continue to …
View article: LINC01235 Promotes Clonal Evolution through DNA Replication Licensing‐Induced Chromosomal Instability in Breast Cancer
LINC01235 Promotes Clonal Evolution through DNA Replication Licensing‐Induced Chromosomal Instability in Breast Cancer Open
Despite the development of HER2‐targeting drugs such as trastuzumab and T‐DXd, treatment resistance is a substantial challenge, often leading to relapse and distant metastasis. Tumor heterogeneity in HER2‐positive breast cancer drives the …
View article: Assessing neoadjuvant treatment response through serum human epidermal growth factor receptor 2 (HER2) dynamics
Assessing neoadjuvant treatment response through serum human epidermal growth factor receptor 2 (HER2) dynamics Open
Our study confirms that reductions in sHER2 levels after C2 are a strong indicator of favorable treatment response in HER2-positive BC patients undergoing NAT. Monitoring sHER2 dynamics early in treatment can serve as a useful, non-invasiv…
View article: DUSP4 enhances therapeutic sensitivity in HER2-positive breast cancer by inhibiting the G6PD pathway and ROS metabolism by interacting with ALDOB
DUSP4 enhances therapeutic sensitivity in HER2-positive breast cancer by inhibiting the G6PD pathway and ROS metabolism by interacting with ALDOB Open
In summary, our study unveils a metabolic reprogramming paradigm in BC, highlighting DUSP4's role in enhancing therapeutic sensitivity in HER2-positive BC cells. DUSP4 interacts with ALDOB, inhibiting G6PD activity and the ROS pathway, est…
View article: Somatic mutations in a multigene panel and impact on prognosis based on <scp>TP53</scp> status in Chinese <scp>HER2</scp>‐positive patients undergoing neoadjuvant therapy: A single‐institution retrospective cohort
Somatic mutations in a multigene panel and impact on prognosis based on <span>TP53</span> status in Chinese <span>HER2</span>‐positive patients undergoing neoadjuvant therapy: A single‐institution retrospective cohort Open
Background Gene mutations play a crucial role in the occurrence and development of tumors, particularly in breast cancer (BC). Neoadjuvant therapy (NAT) has shown greater clinical benefit in HER2‐positive breast cancer. However, further cl…
View article: MNX1 Promotes Anti-HER2 Therapy Sensitivity via Transcriptional Regulation of CD-M6PR in HER2-Positive Breast Cancer
MNX1 Promotes Anti-HER2 Therapy Sensitivity via Transcriptional Regulation of CD-M6PR in HER2-Positive Breast Cancer Open
Although targeted therapy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer has significantly prolonged survival time and improved patients’ quality of life, drug resistance has gradually emerged. This study explor…
View article: CRTAM promotes antitumor immune response in triple negative breast cancer by enhancing CD8+ T cell infiltration
CRTAM promotes antitumor immune response in triple negative breast cancer by enhancing CD8+ T cell infiltration Open
Background Immunomodulatory (IM) subtype triple negative breast cancer (TNBC) has high immune cell signaling, cytokine signaling gene expression, and is more responsive to immunotherapy. The mechanism responsible for this phenomenon is not…
View article: Immediate Breast Reconstruction After Neoadjuvant Chemotherapy
Immediate Breast Reconstruction After Neoadjuvant Chemotherapy Open
Background Breast reconstruction has become an integral component of breast cancer treatment, especially for patients who are unable to undergo breast-conserving surgery after neoadjuvant chemotherapy (NAC). We analyzed factors influencing…
View article: LINC00478-derived novel cytoplasmic lncRNA LacRNA stabilizes PHB2 and suppresses breast cancer metastasis via repressing MYC targets
LINC00478-derived novel cytoplasmic lncRNA LacRNA stabilizes PHB2 and suppresses breast cancer metastasis via repressing MYC targets Open
Background Metastasis is the predominant cause of mortality in patients with breast cancer. Long noncoding RNAs (lncRNAs) have been shown to drive important phenotypes in tumors, including invasion and metastasis. However, the lncRNAs invo…
View article: The Prognostic Values of Androgen Receptor in Breast Cancer
The Prognostic Values of Androgen Receptor in Breast Cancer Open
Context.— Whether androgen receptor (AR) expression can predict prognosis in breast cancer is under debate. Objective.— To analyze, retrospectively, the prognostic and treatment-predictive ability of AR status in breast cancer. Design.— A …
View article: Surgical options of the breast and clinical outcomes of breast cancer patients after neoadjuvant chemotherapy: A single-center retrospective study
Surgical options of the breast and clinical outcomes of breast cancer patients after neoadjuvant chemotherapy: A single-center retrospective study Open
Background Neoadjuvant chemotherapy (NAC) has evolved significantly and has been widely accepted for downstaging disease in early-stage and locally advanced breast cancer patients. Since the optimal surgical intervention for patients recei…
View article: Immunosuppressive lncRNA LINC00624 promotes tumor progression and therapy resistance through ADAR1 stabilization
Immunosuppressive lncRNA LINC00624 promotes tumor progression and therapy resistance through ADAR1 stabilization Open
Background Despite the success of HER2-targeted therapy in achieving prolonged survival in approximately 50% of treated individuals, treatment resistance is still an important challenge for HER2+ breast cancer (BC) patients. The influence …
View article: Cross-talk of four types of RNA modification proteins with adenosine reveals the landscape of multivariate prognostic patterns in breast cancer
Cross-talk of four types of RNA modification proteins with adenosine reveals the landscape of multivariate prognostic patterns in breast cancer Open
Background: Breast cancer (BC) is the most common malignant tumour, and its heterogeneity is one of its major characteristics. N6-methyladenosine (m6A), N1-methyladenosine (m1A), alternative polyadenylation (APA), and adenosine-to-inosine …
View article: Stabilization of CCDC102B by Loss of RACK1 Through the CMA Pathway Promotes Breast Cancer Metastasis via Activation of the NF-κB Pathway
Stabilization of CCDC102B by Loss of RACK1 Through the CMA Pathway Promotes Breast Cancer Metastasis via Activation of the NF-κB Pathway Open
Background Breast cancer is one of the leading causes of cancer-related death among women, and the pathological status of axillary lymph nodes is an important predictor of prognosis. However, the mechanism involved in this early stage of m…
View article: Clinical and Genetic Predictive Models for the Prediction of Pathological Complete Response to Optimize the Effectiveness for Trastuzumab Based Chemotherapy
Clinical and Genetic Predictive Models for the Prediction of Pathological Complete Response to Optimize the Effectiveness for Trastuzumab Based Chemotherapy Open
Background Trastuzumab shows excellent benefits for HER2+ breast cancer patients, although 20% treated remain unresponsive. We conducted a retrospective cohort study to optimize neoadjuvant chemotherapy and trastuzumab treatment in HER2+ b…
View article: Plasma Extracellular Vesicle Long RNA Profiles in the Diagnosis and Prediction of Treatment Response for Breast Cancer
Plasma Extracellular Vesicle Long RNA Profiles in the Diagnosis and Prediction of Treatment Response for Breast Cancer Open
Background: The utility of extracellular vesicle long RNAs (exLRs) as noninvasive biomarkers in breast cancer remains elusive. The purpose of this study was to explore the potential of exLRs as clinically actionable biomarkers for breast c…
View article: A nomogram for predicting axillary pathologic complete response in hormone receptor–positive breast cancer with cytologically proven axillary lymph node metastases
A nomogram for predicting axillary pathologic complete response in hormone receptor–positive breast cancer with cytologically proven axillary lymph node metastases Open
Background The objective of this study was to determine an axillary pathologic complete response (pCR) and its influencing factors in patients with hormone receptor (HR)–positive breast cancer and cytologically proven axillary lymph node m…
View article: Axillary evaluation is not warranted in patients preoperatively diagnosed with ductal carcinoma in situ by core needle biopsy
Axillary evaluation is not warranted in patients preoperatively diagnosed with ductal carcinoma in situ by core needle biopsy Open
Background Patients diagnosed with ductal carcinoma in situ (DCIS) by core needle biopsy (CNB) have a great chance of upstaging to invasive cancer. Positive axillary status can be found in these patients. This study sought to identify clin…
View article: Applications of rib sparing technique in internal mammary vessels exposure of abdominal free flap breast reconstructions: a 12-year single-center experience of 215 cases
Applications of rib sparing technique in internal mammary vessels exposure of abdominal free flap breast reconstructions: a 12-year single-center experience of 215 cases Open
IMVs were used more frequently as the recipient vessels in abdominal free flap breast reconstructions, especially when axillary operation was not performed at the same time. Rib sparing technique had the potential to decrease surgery time,…
View article: Increased Mortality with Repeat Lumpectomy Alone After Ipsilateral Breast Tumor Recurrence
Increased Mortality with Repeat Lumpectomy Alone After Ipsilateral Breast Tumor Recurrence Open
Background The benefit of repeat lumpectomy for ipsilateral breast tumor recurrence (IBTR) after breast conserving surgery is currently inconclusive. Materials and Methods Patients with IBTR with definitive surgery were identified in the S…
View article: Changing patterns and survival improvements of young breast cancer in China and SEER database, 1999−2017
Changing patterns and survival improvements of young breast cancer in China and SEER database, 1999−2017 Open
With the increased early-stage and ER-positive diseases in young patients as well as better systemic treatment strategies, improved survival has been observed in recent years. There has been a substantial de-escalation in surgical therapie…